Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa (NCT07213973)
A Phase 2, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Povorcitinib in Adolescents With Moderate to Severe Hidradenitis Suppurativa
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.
Who can join: Review the eligibility criteria below.
Location: University of Alabama At Birmingham — Birmingham, Alabama
Age range: 12 Years to 17 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (30 Sites)
Showing the first 25 of 30 sites.
- University of Alabama At Birmingham — Birmingham, Alabama
- Medical Dermatology Specialists Phoenix — Phoenix, Arizona
- Saguaro Dermatology — Phoenix, Arizona
- Uconn Health — Farmington, Connecticut
- University of Miami Miller School of Medicine — Miami, Florida
- Skin Research of South Florida, Llc — Miami, Florida
- Trueblue Clinical Research — Tampa, Florida
- Advanced Medical Research Pc — Sandy Springs, Georgia
- Endeavor Health Medical Group — Skokie, Illinois
- Dermatology Skin Cancer Center Leawood — Leawood, Kansas
- Equity Medical — Bowling Green, Kentucky
- Johns Hopkins Univ Schl of Medicine — Baltimore, Maryland
- Skin Oasis Dermatology — Gambrills, Maryland
- Boston Childrens Hospital — Boston, Massachusetts
- Oakland Hills Dermatology Pc — Auburn Hills, Michigan
- Wayne State University Physician Group Dermatology — Detroit, Michigan
- Revival Research Institute, Llc Troy — Troy, Michigan
- University of Missouri Kansas City — Kansas City, Missouri
- Washington University — St Louis, Missouri
- Boeson Research Missoula 2825 Fort Missoula Rd — Missoula, Montana
- University of New Mexico Hospital — Albuquerque, New Mexico
- Geisinger Medical Center — Danville, Pennsylvania
- Bellaire Dermatology Associates Bda — Bellaire, Texas
- Texas Dermatology Research Center — Dallas, Texas
- 3A Research Llc West Location — El Paso, Texas
📞 Contact the Study Coordinator
Phone: (855) 463-3463
Email: medinfo@incyte.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hidradenitis Suppurativa (HS)
- Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense — Phoenix, Arizona
- A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa — Phoenix, Arizona
- Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa — Missouri City, Texas
- A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial) — Irvine, California
- A Study to Evaluate the Efficacy of Botulinum Toxin in Patients With Hidradenitis Suppurativa — Worcester, Massachusetts
- ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa — Chapel Hill, North Carolina
Explore by condition: All Hidradenitis Suppurativa (HS) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.